Director at Intelligent Bio Solutions (INBS) granted 5,000 shares

Rhea-AI Filing Summary

Hurd Jonathan Scott reported acquisition or exercise transactions in this Form 4 filing.

INTELLIGENT BIO SOLUTIONS INC. director Jonathan Scott Hurd received a grant of 5,000 restricted shares of Common Stock on March 18, 2026 under the company’s 2019 Long Term Incentive Plan. The shares vest after 12 months and can be forfeited until vested. Following this award, he holds 5,006 shares directly, with all amounts presented after a 1-for-10 reverse stock split effected on December 15, 2025.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hurd Jonathan Scott

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,000	$0.00	--

Holdings After Transaction: Common Stock — 5,006 shares (Direct)

Footnotes (1)

1. On December 15, 2025, Intelligent Bio Solutions Inc. (the "Issuer") effected a 1-for-10 reverse stock split of the Issuer's common stock ("Common Stock"). The reverse stock split effected in December 2025, and prior reverse stock splits effected by the Issuer, resulted in a reduction in the number of shares held by the reporting person and proportional adjustments to the outstanding equity awards held by the reporting person. Accordingly, all amounts in this Form 4 are presented on a post-reverse split basis. On March 18, 2026, the Issuer granted the reporting person 5,000 restricted shares of Common Stock under the Intelligent Bio Solutions Inc. 2019 Long Term Incentive Plan. The awarded shares are subject to time-based vesting after 12 months and are subject to forfeiture until vested.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hurd Jonathan Scott

(Last) (First) (Middle)

C/O INTELLIGENT BIO SOLUTIONS INC.,

135 WEST 41ST STREET, 5TH FLOOR

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
INTELLIGENT BIO SOLUTIONS INC. [ INBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/18/2026		A		5,000(2)	A	$0	5,006(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On December 15, 2025, Intelligent Bio Solutions Inc. (the "Issuer") effected a 1-for-10 reverse stock split of the Issuer's common stock ("Common Stock"). The reverse stock split effected in December 2025, and prior reverse stock splits effected by the Issuer, resulted in a reduction in the number of shares held by the reporting person and proportional adjustments to the outstanding equity awards held by the reporting person. Accordingly, all amounts in this Form 4 are presented on a post-reverse split basis.

2. On March 18, 2026, the Issuer granted the reporting person 5,000 restricted shares of Common Stock under the Intelligent Bio Solutions Inc. 2019 Long Term Incentive Plan. The awarded shares are subject to time-based vesting after 12 months and are subject to forfeiture until vested.

	/s/ Jonathan Scott Hurd	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did INBS director Jonathan Scott Hurd report in this Form 4?

Director Jonathan Scott Hurd reported receiving 5,000 restricted shares of INTELLIGENT BIO SOLUTIONS INC. common stock. The grant was made on March 18, 2026 under the company’s 2019 Long Term Incentive Plan and increases his direct holdings to 5,006 shares after the transaction.

How many INBS shares does Jonathan Scott Hurd hold after this grant?

After the restricted stock grant, Jonathan Scott Hurd directly holds 5,006 shares of INTELLIGENT BIO SOLUTIONS INC. common stock. This total reflects all adjustments from the company’s 1-for-10 reverse stock split that was effected on December 15, 2025 and prior reverse splits.

What are the vesting terms of the 5,000 INBS restricted shares granted?

The 5,000 restricted shares of INTELLIGENT BIO SOLUTIONS INC. common stock vest based on time, after 12 months from the March 18, 2026 grant date. Until they vest, the shares are subject to forfeiture, meaning Hurd could lose them if vesting conditions are not satisfied.

Was the INBS stock grant to Jonathan Scott Hurd a market purchase?

No, the transaction was a grant or award, not a market purchase. The Form 4 uses transaction code “A” for an acquisition by grant or award, and the per-share price is reported as 0.0000, indicating it was compensation-related rather than an open-market buy.

How did INTELLIGENT BIO SOLUTIONS INC.’s reverse stock split affect this Form 4?

INTELLIGENT BIO SOLUTIONS INC. completed a 1-for-10 reverse stock split of its common stock on December 15, 2025. The company states that all share amounts and equity awards reported in this Form 4, including Hurd’s 5,000-share grant and 5,006-share holdings, are presented on a post-split basis.